Kyntra Bio (KYNB) vs Seres Therapeutics (MCRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Seres Therapeutics is the larger company by market cap ($26.4 million vs $24.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KYNB | MCRB |
|---|---|---|
| Share price | $5.96 | $2.63 |
| Market cap | $24.13M | $26.42M |
| 1-day change | -1.32% | -3.31% |
| YTD return | -32.12% | — |
| 1-year return | -47.72% | — |
| 5-year return | -97.84% | — |
| EPS (TTM) | $-7.64 | $-2.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.65 | $29.98 |
| 52-week low | $5.62 | $2.42 |
| Distance from 52-week high | -48.84% | -91.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +565.60% | +546.39% |
| Average volume | 18.29K | 73.43K |
| Shares outstanding | 4.05M | 10.04M |
| Employees | 34 | 66 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Kyntra Bio
KYNB stock →Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers.
Healthcare · Biotechnology · 34 employees
About Seres Therapeutics
MCRB stock →Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.
Healthcare · Biotechnology · 66 employees
KYNB vs MCRB FAQ
Which is bigger, Kyntra Bio or Seres Therapeutics?
Seres Therapeutics (MCRB) is larger, with a market capitalization of $26.42M compared with $24.13M for Kyntra Bio (KYNB).
Are Kyntra Bio and Seres Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.